首页> 外文期刊>Journal of Clinical Microbiology >Clinical Evaluation of the New High-Throughput Luminex NxTAG Respiratory Pathogen Panel Assay for Multiplex Respiratory Pathogen Detection
【24h】

Clinical Evaluation of the New High-Throughput Luminex NxTAG Respiratory Pathogen Panel Assay for Multiplex Respiratory Pathogen Detection

机译:新型高通量Luminex NxTAG呼吸道病原体检测试剂盒用于多重呼吸道病原体检测的临床评价

获取原文
           

摘要

A broad range of viral and bacterial pathogens can cause acute respiratory tract infection. For rapid detection of a broad respiratory pathogen spectrum, multiplex real-time PCR is ideal. This study evaluated the performance of the new Luminex NxTAG Respiratory Pathogen Panel (NxTAG-RPP) in comparison with the BioFire FilmArray Respiratory Panel (FA-RP) or singleplex real-time PCR as reference. A total of 284 clinical respiratory specimens and 3 influenza A/H7N9 viral culture samples were tested. All clinical specimens were processed and analyzed in parallel using NxTAG-RPP and the reference standard method. The H7N9 viral culture samples were tested using NxTAG-RPP only. Overall, the NxTAG-RPP demonstrated ≥93% sensitivity and specificity for all respiratory targets except human coronavirus OC43 (HCoV-OC43) and HCoV-HKU1. The H7N9 virus was detected by the influenza A virus matrix gene target, while other influenza A virus subtyping gene targets in the panel remained negative. Complete concordance between NxTAG-RPP and FA-RP was observed in 98.8% (318/322) of positive results (kappa = 0.92). Substantial agreement was found for most respiratory targets, but significant differences were observed in human metapneumovirus (P = 0.001) and parainfluenza virus type 3 (P = 0.031). NxTAG-RPP has a higher sample throughput than FA-RP (96 samples versus 1 sample per run) while the turnaround times for NxTAG-RPP and FA-RP were 5 h (up to 96 samples) and 1 h (for one sample), respectively. Overall, NxTAG-RPP demonstrated good diagnostic performance for most respiratory pathogens. The high sample throughput with reasonable turnaround time of this new assay makes it a suitable multiplex platform for routine screening of respiratory specimens in hospital-based laboratories.
机译:广泛的病毒和细菌病原体可以引起急性呼吸道感染。对于快速检测广泛的呼吸道病原体谱,多重实时PCR是理想的选择。这项研究与BioFire FilmArray呼吸小组(FA-RP)或单重实时PCR相比,评估了新型Luminex NxTAG呼吸道病原体小组(NxTAG-RPP)的性能。总共测试了284个临床呼吸道标本和3个A / H7N9流感病毒培养标本。使用NxTAG-RPP和参考标准方法对所有临床标本进行并行处理和分析。仅使用NxTAG-RPP测试了H7N9病毒培养物样品。总体而言,NxTAG-RPP对除人类冠状病毒OC43(HCoV-OC43)和HCoV-HKU1以外的所有呼吸道靶标均显示≥93%的敏感性和特异性。通过甲型流感病毒基质基因靶标检测到H7N9病毒,而小组中其他甲型流感病毒亚型基因靶标仍为阴性。在98.8%(318/322)的阳性结果中(kappa = 0.92),观察到NxTAG-RPP和FA-RP之间完全一致。在大多数呼吸目标中发现基本一致,但在人间质肺病毒( P = 0.001)和3型副流感病毒( P = 0.031)中观察到显着差异。 NxTAG-RPP具有比FA-RP更高的样品通量(96个样品对比每次运行1个样品),而NxTAG-RPP和FA-RP的周转时间分别为5小时(最多96个样品)和1小时(1个样品) , 分别。总体而言,NxTAG-RPP对大多数呼吸道病原体表现出良好的诊断性能。这种新方法的高样品通量和合理的周转时间,使其成为医院实验室常规筛查呼吸道标本的合适多重平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号